Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its competitor.